Physician profile
Christina B Truman
NPI 1568576684
$69,586.97
in general payments reported to CMS, 2019-2025
15 companies · $20K in 2025
The $20K reported for 2025 was more than what 99% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.89 · 2022: $237 · 2023: $27K · 2024: $23K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Travel and Lodging: $17K · Food and Beverage: $6,447 · Honoraria: $3,675 · Consulting Fee: $2,793 · Education: $442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,448.00 |
| Travel and Lodging | $16,504.52 |
| Food and Beverage | $6,447.42 |
| Honoraria | $3,675.00 |
| Consulting Fee | $2,793.00 |
| Education | $441.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $43,183.17 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $24,910.21 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $351.63 | 2023-2025 | Gemtesa, Myfembree |
| Avion Pharmaceuticals | $239.64 | 2022-2023 | Balcoltra |
| Abbvie INC. | $177.31 | 2022-2025 | |
| Acella Pharmaceuticals, LLC | $130.01 | 2023 | NP Thyroid 60 |
| Evofem Biosciences, INC. | $113.19 | 2021-2025 | Phexxi, Solosec, Phexx |
| Pfizer INC. | $108.98 | 2023-2025 | |
| Exeltis, USA INC. | $90.80 | 2023-2024 | Slynd |
| Biogen, INC. | $69.94 | 2024-2025 | Zurzuvae |
| Organon LLC | $65.88 | 2023-2025 | Nexplanon, Nuvaring |
| Shield Therapeutics INC | $56.98 | 2023-2024 | Accrufer |
| Astellas Pharma Global Development | $52.35 | 2025 | Veozah |
| Medtronic, INC. | $20.10 | 2025 | Ligasure |
| Exact Sciences Corporation | $16.78 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Truman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.